Showing results (221-230 of 699) with videos related to

Sort By:
Pageof 70
Cancer|October 14, 2004
Incidence of multiple myeloma in Olmsted County, Minnesota: Trend over 6 decadesRobert A Kyle, Terry M Therneau, S Vincent Rajkumar, et al.
Blood Cancer Journal|May 25, 2026
Prevalence of monoclonal gammopathy of undetermined significance (MGUS) using a sensitive mass spectrometry assay in young individuals 10-49 years of age: a population-based study from the National Health and Nutritional Examination SurveyShaji Kumar, David Murray, Dirk R Larson, et al.
Clinical Lymphoma|March 30, 2005
Prognostic factors and predictors of outcome of immunoglobulin M monoclonal gammopathy of undetermined significanceRobert A Kyle, S Vincent Rajkumar, Terry M Therneau, et al.
Mayo Clinic Proceedings|July 13, 2004
Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years laterRobert A Kyle, Terry M Therneau, S Vincent Rajkumar, et al.
Clinical Lymphoma & Myeloma|April 14, 2009
IgM monoclonal gammopathy of undetermined significance and smoldering Waldenström's macroglobulinemiaRobert A Kyle, Joanne Benson, Dirk Larson, et al.
Blood Advances|March 2, 2022
Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myelomaCharalampos Charalampous, Utkarsh Goel, Stephen M Broski, et al.
The Lancet. Oncology|September 1, 2020
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trialShaji K Kumar, Susanna J Jacobus, Adam D Cohen, et al.
Leukemia|February 24, 2021
Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patientsAlissa Visram, Iuliana Vaxman, Abdullah S Al Saleh, et al.
Blood Cancer Journal|March 27, 2024
Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomideUtkarsh Goel, Charalampos Charalampous, Prashant Kapoor, et al.
Blood Cancer Journal|May 15, 2023
Conditional survival in multiple myeloma and impact of prognostic factors over timeNadine H Abdallah, Alexandra N Smith, Susan Geyer, et al.
Pageof 70